Project Grant R21AI186783
Award Date
7/24/24
Completion Date
5/31/26
Dollars Obligated
$681K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This Project Grant award of $1,766,954.46 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona. The award aims to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). Specifically, the research will determine the location, phenotype, and microenvironment of HIV RNA-expressing cells in secondary...
This federal Project Grant award, valued at $486,057 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel mRNA gene therapy approach to address the challenge of HIV persistence and achieve a functional cure. The key products and services to be delivered under this grant include: Designing and studying cutting-edge mRNA-based interventions to induce HIV...
This $824,331 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the formation and dynamics of the SIV (Simian Immunodeficiency Virus) reservoir. The primary objectives are to investigate the early establishment and persistence of latent viral reservoirs, with a focus on the potential role of naive CD4+ T cells in maintaining the viral reservoir, even...
This federal Project Grant award, totaling $285,816.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this 3-year project, with a start date of September 12, 2024, is to investigate the role of ADP-ribosylation (ADPR) and its associated proteins in modulating HIV-1 latency and reactivation. The research aims to identify global proteomic changes to ADPR during HIV-1...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...
This $800,389 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of this 5-year grant is to evaluate the safety and therapeutic potential of a novel treatment strategy for achieving sustained HIV remission. The proposed approach combines soluble IL-15/IL-15RA-FC with TGF-beta pathway blockade and therapeutic vaccination, to enhance anti-viral immunity and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...